文章预览
SCI 24 October 2024 Perioperative chemotherapy and nivolumab in non-small cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial (Lancet Oncology, IF: 41.6) Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, Joaquín Casal, Manuel Dómine, Bartomeu Massuti, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier de Castro, David Gómez de Antonio, Iván Macia, Santiago Figueroa, Luís Fernández Vago, Virginia Calvo, Ramón Palmero, Belén Sierra-Rodero, Cristina Martínez-Toledo, Marta Molina-Alejandre, Roberto Serna-Blasco, Atocha Romero, Alberto Cruz-Bermúdez CORRESPONDENCE TO: mprovenciop@gmail.com Background 背景 Perioperative immunotherapy improves short-term outcomes in resectable non-small-cell lung cancer (NSCLC). We now report 5-year survival from the NADIM trial to assess its long-term benefit. 围手术期免疫治疗改善可切除非小细胞肺癌（NSCLC）的短期疗效。我们现在报
………………………………
